FDA approves diabetes drug that also helps with weight loss
BY LINDA A. JOHNSON
TRENTON, N.J. – U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.
Danish drugmaker Novo Nordisk said the Food and Drug Administration approved its once-a-week shot for people with Type 2 diabetes. The drug, Ozempic, also known as semaglutide, works by stimulating the body’s own insulin production and reducing appetite.
In one big companyfunded study, Ozempic, on average, reduced long-term blood sugar levels at least 2 ½ times as much as a popular daily diabetes pill, Merck & Co.’s Januvia. It also helped study participants lose two to three times as much weight as those in the comparison group.
Over 56 weeks, patients who got a lower dose of Ozempic lost an average of 9.5 pounds (4.3 kilograms) while those who got a higher dose lost 13.5 pounds (6.1 kilograms). The patients who took Januvia lost an average of 4 pounds (1.9 kilograms).
The 1,200 study participants were also taking one or two standard diabetes medicines.
Novo Nordisk, a leader in diabetes care, has also been testing the drug separately for weight loss alone.
Many Type 2 diabetes patients are overweight or obese, and losing significant weight usually helps them reduce their blood sugar and better control their diabetes. Over time, too high sugar in the blood can damage multiple organs and weaken circulation.
The new drug comes in injector pens and costs about the same as similar weekly drugs: $676 for a four- to six-week supply without insurance. Novo Nordisk already sells a similar once-a-day shot, Victoza.
Ozempic will compete with other popular once-a-week drugs in the same class, including Eli Lilly and Co.’s Trulicity and AstraZeneca PLC’s Bydureon, which don’t produce as much weight loss. However, they all carry warnings about possible serious side effects, including kidney damage and inflammation of the pancreas. They also may be linked to thyroid cancer, so people taking all drugs in the class are being followed via a patient registry.